Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy

HIV Medicine

Volumn 8, Issue 6, 2007, Pages 406-410

  Patterson, Kristine B ^a   Napravnik, S ^a   Eron, J ^a   Keruly, J ^b   Moore, R ^b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Age; Cohort study; Highly active antiretroviral therapy; HIV infection; Sex

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; VIROLOGY; VIRUS INHIBITION;

AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; RNA, VIRAL; SEX FACTORS; VIRAL LOAD;

EID: 34547406133     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00485.x     Document Type: Article

References (37)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2006 Report on the Global AIDS Epidemic. Geneva, Switzerland: UNAIDS, 2006.
2. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2004, Vol. 16. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2005.
3. CASCADE Collaboration. Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. J Acquir Immune Defic Syndr 2003; 34: 76-83.
4. Prins M, Robertson JR, Brettle RP et al. Do gender differences in CD4 cell counts matter? AIDS 1999; 13: 2361-2364.
5. Napravnik S, Poole C, Thomas J, Eron J. Gender differences in HIV RNA levels: A meta-analysis of published studies. J Acquir Immune Defic Syndr 2002; 31: 11-19.
6. Gandhi M, Bacchetti P, Miotti P, Veronese F, Greenblatt R. Does patient sex affect human immunodeficiency levels? Clin Infect Dis 2002; 35: 313-322.
7. Greenblatt RM, Ameli N, Grant RM, Bacchetti P, Taylor RN. Impact of the ovulatory cycle on virologic and immunologic markers in HIV-infected women. J Infect Dis 2000; 181: 82-90.
8. van Benthem BH, Vernazza P, Coutinho RA, Prins M. The impact of pregnancy and menopause on CD4 lymphocyte counts in HIV-infected women. AIDS 2002; 16: 919-924.
9. Moore R. Understanding the clinical and economic outcomes of HIV therapy: The Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr 1998; 17 (Suppl.): S38-S41.
10. Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, Eron JJ Jr. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 2005; 40: 34-40.
11. Greenland S. Model-based estimation of relative risks and other epidemiologic measures in studies of common outcomes and in case-control studies. Am J Epidemiol 2004; 160: 301-305.
12. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 2003; 17: 2159-2168.
13. Fletcher CV, Jiang H, Brundage RC et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis 2004; 189: 1176-1184.
14. Currier JS, Spino C, Grimes J et al. Differences between women and men in adverse events and CD4 responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000; 24: 316-324.
15. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81-87.
16. Bersoff-Matcha SJ, Miller WC, Aberg JA et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32: 124-129.
17. CASCADE Collaboration. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis. Lancet 2000; 355: 1131-1137.
18. Prins M, Meyer L, Hessol NA. Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. AIDS 2005; 19: 357-370.
19. Giordano TP, Wright JA, Hasan MQ, White AC Jr, Graviss EA, Visnegarwala F. Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis 2003; 37: 433-437.
20. Moore AL, Sabin CA, Johnson MA, Phillips AN. Gender and clinical outcomes after starting highly active antiretroviral treatment: A cohort study. J Acquir Immune Defic Syndr 2002; 29: 197-202.
21. Moore AL, Mocroft A, Madge S et al. Gender differences in virologic response to treatment in an HIV-positive population: A cohort study. J Acquir Immune Defic Syndr 2001; 26: 159-163.
22. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001; 15: 2251-2257.
23. Chene G, Sterne JA, May M et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: Analysis of prospective studies. Lancet 2003; 362: 679-686.
24. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360: 119-129.
25. Nicastri E, Angeletti C, Palmisano L et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 2005; 19: 577-583.
26. Kuyper LM, Wood E, Montaner JS, Yip B, O'Connell JM, Hogg RS. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-infected patients in a population-based cohort. J Acquir Immune Defic Syndr 2004; 37: 1470-1476.
27. Moore AL, Kirk O, Johnson AM et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: The gender issue revisited. J Acquir Immune Defic Syndr 2003; 32: 452-461.
28. Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000; 24: 475-482.
29. Manfredi R, Calza L, Cocchi D et al. Antiretroviral treatment and advanced age: Epidemiologic, laboratory, and clinical features in the elderly. J Acquir Immune Defic Syndr 2003; 33: 112-114.
30. Viard JP, Mocroft A, Chiesi A et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: Evidence from the EuroSIDA study. J Infect Dis 2001; 183: 1290-1294.
31. Orlando G, Meraviglia P, Cordier L et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med 2006; 7: 549-557.
32. Tumbarello M, Rabagliati R, Donati K et al. Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 2004; 4: 46-56.
33. Kalayjian RC, Landay A, Pollard RB et al. Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: Association of age and HIV infection with naive CD8 cell depletion, reduced expression of CD28 on CD8 cells, and reduced thymic volumes. J Infect Dis 2003; 187: 1924-1933.
34. Autran B, Carcelain G, Li TS et al. Positive effects of combined antiretroviral therapy on CD4T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-116.
35. Pakker NG, Notermans DW, de Boer RJ et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nat Med 1998; 4: 208-214.
36. Fantry LE, Zhan M, Taylor GH, Sill AN, Flaws JA. Age of menopause and menopausal symptoms in HIV-infected women. AIDS Patient Care STDs 2005; 19: 703-709.
37. McKinlay S. The normal menopause transition: An overview. Maturitas 1996; 23: 137.